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Abstract
Background
The origin and spread of tuberculosis (TB) in Tasmania and the types of strains of Mycobac-
terium tuberculosis complex (MTBC) present in the population are largely unknown.
Objective
The aim of this study was to perform the first genomic analysis of MTBC isolates from Tas-
mania to better understand the epidemiology of TB in the state.
Methods
Whole-genome sequencing was performed on cultured isolates of MTBC collected from
2014–2016. Single-locus variant analysis was applied to determine the phylogeny of the iso-
lates and the presence of drug-resistance mutations. The genomic data were then cross-ref-
erenced against public health surveillance records on each of the cases.
Results
We determined that 83.3% of TB cases in Tasmania from 2014–2016 occurred in non-Aus-
tralian born individuals. Two possible TB clusters were identified based on single locus vari-
ant analysis, one from November-December 2014 (n = 2), with the second from May-
August 2015 (n = 4). We report here the first known isolate of multi-drug resistant (MDR)
M. tuberculosis in Tasmania from 2016 for which we established its drug resistance muta-
tions and potential overseas origin. In addition, we characterised a case of M. bovis TB in a
Tasmanian-born person who presented in 2014, approximately 40 years after the last con-
firmed case in the state’s bovids.
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Conclusions
TB in Tasmania is predominantly of overseas origin with genotypically-unique drug-suscep-
tible isolates of M. tuberculosis. However, the state also exhibits features of TB that are
observed in other jurisdictions, namely, the clustering of cases, and drug resistance. Early
detection of TB and contact tracing, particularly of overseas-born cases, coordinated with
rapid laboratory drug-susceptibility testing and molecular typing, will be essential for Tasma-
nia to reach the World Health Organisation’s TB eradication goals for low-incidence
settings.
Introduction
There are few descriptions in the literature describing the epidemiology of tuberculosis (TB) in
Tasmania or the types of strains of Mycobacterium tuberculosis present in its population. Tas-
mania is a small island state in Australia with approximately 0.5 million people [1]. European
settlement of its capital, Hobart, began when it was founded as a penal colony in 1803 by Colo-
nel David Collins who came to Australia with the First Fleet in 1788. The earliest documented
evidence of TB in Tasmania comes from Collins who reported that among 36 ill people in his
Hobart settlement in 1804, one had consumption [2]. The first recorded deaths from TB in the
Tasmanian Aboriginal population occurred between 1835 and 1838 on Flinders Island, situ-
ated to the north east of the main Tasmanian island, where they had been relocated from 1830
[2]. The burden of TB in the state increased until reaching a peak of 248 cases in 1940 that cor-
responded to an incidence rate of 103.8/100,000 in Tasmania compared to the national inci-
dence rate of 59.3/100,000 in Australia at that time [3].
Today, Tasmania is considered a low TB-burden state with an incidence rate of 1.7/100,000
persons compared to 5.7/100,000 nationally in 2014 [4]. There are a number of features of TB
in the state that are of interest. Firstly, TB in Tasmania has been considered to consist of iso-
lated unique cases that have been imported from other jurisdictions. Secondly, the state has
been free of multi-drug resistant forms of TB. Thirdly, as part of the Brucellosis and Tubercu-
losis Eradication Campaign (BTEC) in Australia, bovine TB disease was eradicated from Tas-
manian cattle herds in 1975 thus, eliminating the primary source of human cases of M. bovis
TB in the state [5].
In this study, we performed an in-depth analysis of the types of MTBC strains isolated in
Tasmania between 2014 and 2016 using whole-genome sequencing. We then correlated geno-
mic information with public health surveillance data to better define the epidemiology of TB
in Tasmania.
Methods
Study design
Samples from 18 cultured isolates collected in Tasmania from 2014 to 2016, inclusive, were
available for this study. This represents 62.1% of total TB notifications that occurred during
this time period (n = 29) [6]. Diagnostic laboratory and clinical data were obtained from the
Royal Hobart Hospital, Launceston General Hospital, and the Victorian Infectious Diseases
Reference Laboratory (VIDRL). Samples were sent to the School of Medicine, University of
Tasmania, for next generation sequencing and whole-genome bioinformatics analysis. Ethics
approval for this study was obtained from the Tasmanian Health and Medical Human
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Research Ethics Committee (H0016214). A waiver of consent was acquired as the study was an
observational non-interventional analysis of MTBC isolates and de-identified data that were
obtained from routine laboratory testing.
Sample processing, culture, and drug susceptibility testing
Specimens from patients suspected of having tuberculosis were cultured using both solid
(Brown and Buckle agar, Lo¨wenstein-Jensen agar) and liquid media (Mycobacterial Growth
Indicator Tubes (MGIT)) in accordance with standard protocols for mycobacterial growth [7].
Ziehl-Neelsen staining, TB MPT64 antigen test (Standard Diagnostics Bioline TB MPT64 anti-
gen test) and TB PCR (GenXpert, Cepheid) were performed on positive cultures. The isolates
were supplied to a reference laboratory for further characterisation. Drug-susceptibility testing
was performed using the MGIT system [7].
Genomic DNA isolation
1.5 mL of heat-inactivated mycobacterial cultures were centrifuged at 8,000 rpm for 3 minutes
at room temperature. The cell pellet was resuspended in 200 μL phosphate-buffered saline and
treated with 25 μL of 10 mg/mL lysozyme and incubated at 37˚C for 1 hour followed by 95˚C
for 15 minutes. 30 μL proteinase K (10 mg/mL) were added and the sample was incubated at
55˚C for 30 minutes. A Qiagen DNeasy Blood and Tissue kit was then used to extract myco-
bacterial genomic DNA as per the manufacturer’s instructions and the DNA was eluted with
200 μL of Buffer AE. 1 μL of RNase A (7000 units/mL, Qiagen) was added to 50 μL of genomic
DNA eluent and incubated at room temperature for 1 hour. The genomic DNA was further
purified using a High Pure PCR Template Preparation Kit as per the manufacturer’s instruc-
tions (Roche) and quantified using the Quant-iT Qubit™ dsDNA HS Assay Kit (Thermo Fisher
Scientific).
Whole genome sequencing and data analysis
Purified genomic DNA was tagged and amplified using a Nextera1 XT DNA Library Prepara-
tion Kit and Nextera1 XT Index Kit as per the manufacturer’s (Illumina) instructions. The
libraries generated were cleaned using Agencourt AMPure XP beads, normalized and then
pooled. The concentration of the pooled library was determined by qPCR using a KAPA
Library Quantification Kit. 15 pM of the pooled library were loaded into a MiSeq Reagent Kit
v2 cartridge and run on an Illumina MiSeq instrument generating paired-end reads of 150
base pairs (bp) (maximum). The fastq sequence files were collected and analysed using Gen-
eious software suite (R 9.5) [8]. Paired-end reads were trimmed (error probability limit of
0.05) and then mapped (random multiple base matches) to the publicly-available annotated
genome of M. tuberculosis reference strain H37Rv (accession number NC_000962.3) [9] using
a maximum variant p-value of 10−6 when exceeding 65% bias. Single-locus variations (SLV)
were called at a minimum variant frequency of 95% and a minimum mean genome coverage
of 20, and were annotated as previously described [10]. Mycobacterial lineage was predicted
with TB Profiler [11] and mutations associated with drug resistance were detected using the
PhyResSE database [12] followed by manual checking of the sequence. A maximum likelihood
phylogenetic inference tree was built in PhyML using the generalised time reversible (GTR)
substitution model [13].
Epidemiology of tuberculosis in Tasmania
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TB epidemiological analysis
A threshold of5 single nucleotide polymorphisms (SNPs) between M. tuberculosis isolates
has previously been proposed as an indicator of recent TB transmission between patients,
while >12 SNP differences between isolates has been considered as evidence against recent
transmission [14–16]. SNP distances between TB isolates can be affected by factors such as
time between patient sampling, local TB incidence, and homogeneity of M. tuberculosis strains
in some regions [17, 18]. Therefore, for isolates that were within 5 SNP differences of one
another, additional epidemiological data were used. The definition of a possible cluster was
based on the National Tuberculosis Advisory Committee of Australia’s guidelines which state
that “A ‘possible cluster’ will be any 2 or more active cases with the same genotype as defined
by the method used where temporal and geospatial association is plausible but no direct epide-
miological link is identified” [19]. Each M. tuberculosis isolate in this work was characterised
based on SNP differences to other members of the same global lineage, and the presence of
spatiotemporal links between cases. Furthermore, in silico spoligotyping of the isolates was
performed using the Total Genotyping Solution for TB (TGS-TB) database [20] and compared
with published data on MTBC genotypes in the patient’s country/region of origin.
Results
Relative distribution of MTBC lineages in Tasmania
Cases were 72.2% male (n = 13), 27.8% female (n = 5) (Table 1). The age of patients at date of
specimen collection ranged from 3 months to 70 years of age with a mean age of 33.6 years.
77.7% (n = 14) of cases were pulmonary and 22.2 (n = 4) were extra-pulmonary. 83.3% of cases
(n = 15) were non-Australian born and 16.7% (n = 3) were Australian-born (Table 1).
Table 1. Demographic and specimen information for tuberculosis cases (n = 18) in Tasmania from 2014 to 2016. Demographic variables on the TB cases and speci-
men types were recorded. Cases were 72.2% male and 27.8% female. The mean TB patient age was 33.6 years (range 0–70 years).
Isolate Name Age Range of Patient (years) Specimen Type Year of Specimen Collection MTBC Lineage Patient Country of Origin
RHH2 20–39 Sputum 2015 1 Philippines
RHH3 60 Sputum 2015 3 Nepal
RHH4 20–39 Sputum 2016 4 Thailand
RHH5 20–39 Paraspinal aspirate 2015 1 Myanmar/Malaysia
RHH6 20–39 Osteomyelitis 2014 3 Nepal
RHH7 40–59 Sputum 2014 4 New Zealand
RHH8 20–39 Sputum 2016 2 Malaysia
RHH9 <5 Gastric aspirate 2014 4 New Zealand
RHH10 20–39 Sputum 2016 3 Nepal
RHH11 40–59 Sputum 2015 3 Nepal
RHH12 <5 Gastric aspirate 2016 1 Philippines
RHH13 20–39 Sputum 2015 3 Nepal
RHH14 <5 Gastric aspirate 2015 3 Nepal
RHH15 60 Sputum 2014 4 Australia
TTB1 60 Urine 2016 M. bovis BCG Australia
TASMDR1 20–39 Tissue 2016 2 Vietnam
TTB3 20–39 Sputum 2016 1 Philippines
TASMB14 60 Sputum 2014 M. bovis Australia
MTBC, Mycobacterium tuberculosis complex
https://doi.org/10.1371/journal.pone.0192351.t001
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Whole-genome sequence data were obtained for the 18 TB isolates analysed from 2014–
2016. The phylogenetic lineage of each isolate was determined using the PhyResSE and TB
Profiler databases [11, 12]. The most common lineage among the samples analysed was the
East-African Indian Lineage 3 (n = 6, 33.3%) followed by the Euro-American Lineage 4 (n = 4,
22.2%), Indo-Oceanic Lineage 1 (n = 4, 22.2%), and East-Asian Lineage 2 (n = 2, 11.1%) (Fig
1). In addition, cases of TB due to M. bovis (n = 1) and M. bovis BCG (n = 1) were recorded in
2014 and 2016, respectively.
Molecular epidemiological clustering of TB cases
A maximum likelihood phylogenetic inference tree generated using PhyML revealed grouping
of the different isolates into specific clades which were in agreement with the lineage analysis
performed using the PhyResSE and TB Profiler databases (Fig 2). In addition, the phylogenetic
tree revealed possible genetic clusters of isolates within Lineages 3 and 4.
The Lineage 3 cluster consisted of four isolates (RHH3, RHH11, RHH13, and RHH14)
which exhibited zero SLV differences with respect to one another. Based on the proposed
threshold of5 SNPs, from Walker and others [14, 15], this is indicative of recent transmis-
sion. The isolates were collected in Tasmania from May to August 2015 from drug-susceptible
cases of pulmonary TB. The patients were household contacts and were originally from Nepal.
A previous analysis of 261 M. tuberculosis isolates collected in Nepal from pulmonary TB
patients between August 2009 and August 2010 using spoligotyping and real-time PCR analy-
sis of SNPs found that the most frequent M. tuberculosis lineage was Lineage 3 (40.6%) [21].
The in silico spoligotype of all four Tasmanian Lineage 3 cluster isolates matched Spoligotype
International Type 26 of the CAS1_Delhi spoligotyping family which was found to account for
approximately 50% of Lineage 3 M. tuberculosis isolates in the previous analysis of Nepal TB
cases (Fig 3) [21].
Fig 1. Relative frequency of Mycobacterium tuberculosis complex (n = 18) isolates in Tasmania from 2014 to 2016.
https://doi.org/10.1371/journal.pone.0192351.g001
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The Lineage 4 cluster comprised two isolates (RHH7 and RHH9) which exhibited zero SLV
differences with respect to one another. The isolates were collected in Tasmania from Novem-
ber to December 2014 from drug-susceptible cases of pulmonary TB. The patients were house-
hold contacts and were originally from New Zealand. From an earlier study involving 487
MTBC isolates collected in New Zealand from January 2010 to December 2011, the most prev-
alent lineage was Lineage 4 which made up 37.8% of TB cases in the general population and
70.5% of cases in the New Zealand-born population [23].
The remaining MTBC isolates (n = 12) were phylogenetically unique with respect to one
another with>50 SNP differences between them. The closest isolates from this group were iso-
lates TTB3 and RHH12 which differ by 74 single-locus variations and belong to Indo-Oceanic
Lineage 1. We do not have epidemiological evidence that these patients formed a probable
cluster. Both patients were originally from the Philippines where Lineage 1 is highly dominant
among TB isolates [24, 25].
Fig 2. Phylogenetic relationship of Mycobacterium tuberculosis complex isolates in Tasmania from 2014 to 2016. TASMB14 and TTB1 constitute
isolates of M. bovis and M. bovis BCG, respectively. The Gagneux lineage numbers are indicated for the other isolates. Lineage 2 isolate TASMDR1 is a
multi-drug resistant isolate of Mycobacterium tuberculosis. Lineage 3 isolates RHH3, 11, 13 and 14 are identical (zero SNP differences with respect to
one another) and form an epidemiological cluster as do Lineage 4 isolates RHH7 and RHH9. The phylogenetic tree was built using PhyML (Generalised
Time Reversible substitution model).
https://doi.org/10.1371/journal.pone.0192351.g002
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First confirmed case of MDR-TB in Tasmania
An overseas-born individual tested positive for TB infection in an Interferon Gamma Release
Assay (IGRA) test in 2016 but did not exhibit symptoms of TB, had a normal chest x-ray, and
was sputum culture negative. The patient presented with developed abdominal pain consistent
with colitis later in 2016 and a colon biopsy sample was subsequently taken. The colon tissue
specimen was smear-negative but culture-positive for Mycobacterium tuberculosis. MGIT
based drug-susceptibility testing performed on this extra-pulmonary isolate at VIDRL revealed
that it was resistant to isoniazid, rifampicin, ethambutol, pyrazinamide making it the first con-
firmed case of MDR-TB to have occurred in Tasmania. The isolate was recorded as sensitive to
ethionamide, amikacin, capreomycin, kanamycin, ofloxacin and moxifloxacin.
Genomic DNA of the Tasmanian MDR-TB isolate (TASMDR1) was sequenced on an Illu-
mina MiSeq. Paired-end reads were mapped to the M. tuberculosis H37Rv reference genome
by Burrows-Wheeler Alignment producing a mapped-read depth of 73.7-fold, covering
97.36% of the H37Rv genome. A consensus sequence was called using SAMtools generating a
4,320,496-bp draft assembly. With respect to reference H37Rv genome, 1,566 SLVs were
detected in the TASMDR1 assembled genome, of which 874 were non-synonymous. An analy-
sis was then performed to identify SLVs which correlated with phenotypic drug resistance.
The genome of TASMDR1 displayed single-nucleotide polymorphisms in genes correlating
Fig 3. Distribution of in silico generated spoligotypes across the culture-positive Tasmanian TB isolates analysed from 2014–2016. aThe in silico
derived spoligotype of the four Tasmanian Lineage 3 cluster isolates (RHH3, RHH11, RHH13, RHH14) and a fifth Lineage 3 isolate (RHH10) matched
Spoligotype International Type 26 of the CAS1_Delhi spoligotyping family which accounted for approximately 50% of Lineage 3 M. tuberculosis isolates
in Nepal in a previous analysis [21]. bThe in silico derived spoligotype of the M. bovis isolate (TASMB14) matches that of human M. bovis cases that were
reported in other Australian states/territories between 1977 and 1989 [22].
https://doi.org/10.1371/journal.pone.0192351.g003
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with antimicrobial drug resistance when analysed using the PhyResSE database [12]. These
included high confidence mutations in the genes katG (aGc/aCc, S315T) and rpoB (gAc/gGc,
D435G; tCg/tTg, S450L) which are associated with M. tuberculosis resistance to isoniazid and
rifampicin, respectively [26–28] (Table 2).
Further mutations were detected in the embB (Atg/Gtg, M306V) and pncA (cCg/cTg, P62L)
genes that underlie resistance to ethambutol and pyrazinamide, respectively [29–32] (Table 2).
In addition, an additional A/C substitution was detected at position 514 of the 16S rRNA
gene, rrs (MTB000019) that is associated with streptomycin resistance [33, 34] (Table 2). The
TASMDR1 isolate was predicted to belong to East Asian Lineage 2, sub-lineage Beijing, by the
PhyResSE and TB Profiler databases [11, 12]. Furthermore, the isolate exhibited a polymor-
phism in the mutT2 gene (Gga/Cga, G58R) which is associated with so-called ‘Modern’ Beijing
strains [35, 36]. The patient was originally from Viet Nam and had known household contact
with an active case of TB that was confirmed in Viet Nam in 2012. The isolate from this 2012
case was recorded as resistant to isoniazid, rifampicin, ethambutol, pyrazinamide and strepto-
mycin from MGIT based drug-susceptibility testing.
Case of M. bovisTB in Tasmania
Isolate TASMB14 was collected in Tasmania in 2014 from a sputum specimen taken from a
drug-susceptible case of pulmonary TB in an Australian-born person. Risk factors associated
with this case included age (70 years) and chronic obstructive pulmonary disease co-morbid-
ity. The genome sequence of the isolate revealed that it contains the Rv2043c (pncA) polymor-
phism, Cac/Gac, H57D, and the RD1 region genes Rv3871 to Rv3879c, confirming it as M.
bovis. The in silico derived spoligotype of TASMB14 matches that of other human M. bovis
cases that were reported elsewhere in Australia between 1977 and 1989 [22] (Fig 3).
Discussion
In this study, we provide the first in-depth analysis of the molecular epidemiology of tubercu-
losis in Tasmania. MTBC isolates collected from culture-positive cases of TB in Tasmania
from 2014 to 2016, were examined. The most common lineage detected among the Tasmanian
samples analysed was the East-African Indian Lineage 3 (33.3%) followed by the Euro-Ameri-
can Lineage 4 (22.2%), Indo-Oceanic Lineage 1 (22.2%), and the East-Asian Lineage 2 (11.1%)
(Fig 1). Individual cases of TB due to M. bovis and M. bovis BCG were notified in 2014 and
2016, respectively.
Our whole-genome sequence analyses identified two possible clusters of M. tuberculosis
among the Tasmanian cases, one belonging to Lineage 3 and the other belonging to Lineage 4.
The Lineage 3 cluster, consisted of four isolates separated by zero SLVs which is indicative of
recent transmission between the patients based on previously-established SNP thresholds [14,
Table 2. Mutations detected in the genome of the TASMDR1 isolate that confer resistance to anti-tubercular drugs. Six mutations that have been associated with
anti-tubercular drug resistance were identified. The mutations listed in the rpoB, katG, pncA, and embB genes were classified as high confidence SNPs with respect to resis-
tance to rifampicin, isoniazid, pyrazinamide and ethambutol, respectively, by the PhyResSE database [12]. In addition, an A/C substitution was detected at position 514 of
the 16S rRNA gene, rrs (MTB000019) that is associated with streptomycin resistance [33, 34].
Drug Gene Locus Tag Mutation Genome Location Substitution
Rifampicin rpoB Rv0667 gAc / gGc, tCg /tTg 761110, 761155 D435G, S450L
Isoniazid katG Rv1908c aGc / aCc 2155168 S315T
Pyrazinamide pncA Rv2043c cCg / cTg 2289057 P62L
Ethambutol embB Rv3795 Atg / Gtg 4247429 M306V
Streptomycin rrs MTB000019 A / C 1472359 a514c
https://doi.org/10.1371/journal.pone.0192351.t002
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15]. The isolates were collected within a three-month period from household contacts who
originated from Nepal. The in silico generated spoligotype of the four Lineage 3 cluster isolates
matches Spoligotype International Type 26 of the CAS1_Delhi spoligotyping family. This par-
ticular spoligotype was common among TB cases in Nepal, constituting approximately 50% of
Lineage 3 isolates, and 20% of total TB isolates, in an earlier study (Fig 3) [21].
In this work, we describe the first documented case of MDR-TB in Tasmania. This case was
detected in the second half of 2016 in an overseas-born individual who had earlier moved
from Viet Nam to Tasmania. The isolate, TASMDR1, which belongs to the East-Asian Lineage
2, was confirmed as being resistant to isoniazid, rifampicin, ethambutol and pyrazinamide in
phenotypic drug-susceptibility testing. Furthermore, genome sequencing identified an a514c
mutation in the rrs locus (MTB000019) that is associated with streptomycin resistance. A
household contact of the patient had been diagnosed with pulmonary MDR-TB in Viet Nam
in 2012. The isolate from this 2012 case was recorded as resistant to isoniazid, rifampicin, eth-
ambutol, pyrazinamide, and streptomycin in MGIT culture-based drug-susceptibility testing.
Based on the equivalent drug-resistance profiles of the two MDR-TB cases, it is likely that the
Tasmanian case contracted the MDR strain of M. tuberculosis from the household contact
some time previously and that the infection remained latent until reactivating as extrapulmon-
ary MDR-TB in 2016. A recent study by Fox and colleagues conducted in Viet Nam found that
household contacts of patients with MDR-TB have a higher risk of becoming tuberculin-skin
test positive and of developing active TB compared to contacts of drug-susceptible TB [37].
While the proportion of TB cases in Australia that are MDR is currently under 2% (22
MDR-TB cases out of 1,263 TB notifications in 2013), the estimated costs associated with treat-
ing a case of TB increase substantially when going from drug-susceptible TB (USD$17,000 in
the USA, €10,282 in 15 EU countries, per case) to multi-drug resistant TB (USD$134,000 in
the USA, €57,213 in 15 EU countries, per case) [38, 39]. It was previously estimated that man-
agement of one case of extensively drug-resistant (XDR) TB in 2012 cost Queensland Health
in the region of AUD $500,000 [40]. Hence, vigilance will need to be maintained with respect
to the tracing of contacts of previous TB cases, especially MDR-TB cases, and the early detec-
tion of drug resistance in Tasmanian isolates.
Human TB caused by M. bovis was reported in Tasmania in 2014, nearly 40 years after the
last confirmed case of bovine TB in the state in 1975 [5]. The pulmonary form of disease was
diagnosed in a male aged70 years. The source of this infection is unknown but a possibility
is reactivation of a latent M. bovis infection acquired during earlier rural exposure to M. bovis
prior to the elimination of bovine TB disease in Tasmania. The in silico derived spoligotype of
the isolate, TASMB14, matches that of previously-described human M. bovis cases that were
reported in other Australian states and territories between 1977 and 1989 [22] (Fig 3). As
noted in 1999 by Cousins et al., “because of the usual long incubation periods that can occur
between infection and development of disease, and because of the possibility of disease reacti-
vation, especially in elderly or immunocompromised patients, human tuberculosis caused by
M. bovis is likely to continue to be diagnosed for many years to come” [41].
In the majority of the Tasmanian cases analysed from 2014 to 2016, 83.3% of patients
(n = 15) were born overseas. This corresponds with 89.2% and 87.6% of TB notifications
nationally recorded in the overseas-born population in 2012 and 2013, respectively [42]. A
number of European studies have found that immigrants are not a major source of TB infec-
tion for the native-born population [43, 44]. Sandgren and colleagues in their systematic
review concluded, that “TB in a foreign-born population does not have a significant influence
on TB in the native population in EU/EEA” [45]. In our study, we did not find evidence of
transmission of TB from the overseas-born cases to the Australian-born population. Neverthe-
less, targets have been set for low incidence jurisdictions by the World Health Organisation for
Epidemiology of tuberculosis in Tasmania
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the pre-elimination of TB by 2035 (defined as<10 TB cases per million population), and the
elimination of TB by 2050 (<1 TB case per million population) [46]. The incidence rate of TB
in Tasmania currently sits at approximately 16 per million population (1.6/100,000) [42].
Hence, a 60% drop in TB cases by 2035, and a 95% drop in TB cases by 2050 are required in
Tasmania for the state to meet international targets.
A common trend seen in low TB burden countries is decreasing TB in the native-born pop-
ulation and increasing TB in the migrant population as a proportion of total cases [47]. There-
fore, bringing TB rates into line with the World Health Organisation’s goals will require efforts
to reduce TB incidence in the foreign-born population. A major emphasis in Australia is
placed upon pre-immigration screening. Visa applicants who are 11 years or older must
undergo a chest x-ray and potentially, other diagnostic tests. If active TB is found, Australian
law does not permit the granting of a visa until the applicant has completed treatment and has
been declared free of active TB [48]. Pre-entry screening of foreign-born individuals is not spe-
cifically designed for the detection of latent tuberculosis infection (LTBI). However, most TB
cases among the foreign-born population in industrialised countries are believed to be due to
reactivation of LTBI rather than continuation of an existing case of active TB [49, 50]. In addi-
tion, molecular epidemiological studies have found a strong association between the lineage of
the MTBC strain isolated from a migrant patient and the predominant lineage found in their
region of origin [23–25]. In our study, all Lineage 3 (Central Asian (CAS)/Delhi) cases were in
individuals from the Indian sub-continent where this lineage is prevalent [51]. It is probable
that a number of the overseas-born patients who presented with TB in Tasmania had acquired
M. tuberculosis infection prior to their arrival in the state or in Australia. Therefore, further
consideration will need to be given to the management of TB in the migrant population in Tas-
mania in order to reduce the incidence of the disease in the state.
Conclusions
In summary, our work provides the first extensive analysis of the molecular epidemiology of
tuberculosis in Tasmania. It identified the presence of two phylogenetic clusters of identical
isolates of M. tuberculosis which is indicative of recent transmission of TB among household
contacts. In addition, it established the genetic basis of the resistance exhibited by Tasmania’s
first confirmed case of MDR-TB. Our study highlights that while the incidence of TB in Tas-
mania is comparatively low, challenges remain with regard to the management of the disease
in the migrant population, particularly from high TB prevalence countries, which will need to
be overcome for the state to meet the World Health Organisation’s 2035 and 2050 TB eradica-
tion goals.
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